

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**AMGEN INC**

2. Address:

555 13th Street, NW Suite 600W, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: JEWEL K. SMITH

Telephone: 2025859625

E-mail (optional): jewels@amgen.com

Senate ID #: 3867-12

House ID #:

7. Client Name:  Self

## TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 9,080,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: AMGEN INC Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

Intellectual property and process patent issues S. 1145 and S. 1908 | Patent Reform Act of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ANTORCHA, L. NICOLE

Covered Official Position (if applicable): N/A

Name: BEIER, DAVID

Covered Official Position (if applicable): N/A

Name: BURGESS, CHAKA

Covered Official Position (if applicable): N/A

Name: CURRIE, RODGER

Covered Official Position (if applicable): N/A

Name: GRECO, KIMBERLY

Covered Official Position (if applicable): N/A

Name: GUARDUCCI, MARA

Covered Official Position (if applicable): N/A

Name: KERNS, JESSE

Covered Official Position (if applicable): N/A

Name: MANDELL, REBECCA

Covered Official Position (if applicable): N/A

Name: MOON, HOWARD

Covered Official Position (if applicable): N/A

Name: O'BRIEN, WILLIAM

Covered Official Position (if applicable): N/A

Name: OLSEN, SCOTT

Covered Official Position (if applicable): N/A

Name: RHEE, HELEN

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMGEN INC Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Follow-On-Biologics S. 623 and H.R. 1038 | Access to Life-Saving Medicines Act H.R. 1956 | Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 | Prescription Drug User Fee Amendments of 2007 H.R. 2900 | Food and Drug Administration Amendments Act of 2007

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
Office of Management & Budget (OMB)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ANTORCHA, L. NICOLE  
Covered Official Position (if applicable): N/A  
Name: BEIER, DAVID  
Covered Official Position (if applicable): N/A  
Name: BURGESS, CHAKA  
Covered Official Position (if applicable): N/A  
Name: CURRIE, RODGER  
Covered Official Position (if applicable): N/A  
Name: FOX, ANDREW  
Covered Official Position (if applicable): N/A  
Name: GUARDUCCI, MARA  
Covered Official Position (if applicable): N/A  
Name: KERNS, JESSE  
Covered Official Position (if applicable): N/A  
Name: MANDELL, REBECCA  
Covered Official Position (if applicable): N/A  
Name: MOON, HOWARD  
Covered Official Position (if applicable): N/A  
Name: MOORE, THOMAS  
Covered Official Position (if applicable): N/A  
Name: O'BRIEN, WILLIAM  
Covered Official Position (if applicable): N/A  
Name: OLSEN, SCOTT  
Covered Official Position (if applicable): N/A  
Name: PORTNER, GREGORY  
Covered Official Position (if applicable): N/A  
Name: RHEE, HELEN  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMGEN INC Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Implementation of H.R. 1 Medicare Prescription Drug & Modernization Act of 2003 Medicare coverage and reimbursement of Erythropoiesis-Stimulating Agents Implementation of Medicaid Drug Rebate provisions of the Deficit Reduction Act of 2005

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ANTORCHA, L. NICOLE

Covered Official Position (if applicable): N/A

Name: BEIER, DAVID

Covered Official Position (if applicable): N/A

Name: BURGESS, CHAKA

Covered Official Position (if applicable): N/A

Name: CURRIE, RODGER

Covered Official Position (if applicable): N/A

Name: GUARDUCCI, MARA

Covered Official Position (if applicable): N/A

Name: KERNS, JESSE

Covered Official Position (if applicable): N/A

Name: MANCILL, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: MANDELL, REBECCA

Covered Official Position (if applicable): N/A

Name: MOON, HOWARD

Covered Official Position (if applicable): N/A

Name: MOORE, THOMAS

Covered Official Position (if applicable): N/A

Name: O'BRIEN, WILLIAM

Covered Official Position (if applicable): N/A

Name: OLSEN, SCOTT

Covered Official Position (if applicable): N/A

Name: PORTNER, GREGORY

Covered Official Position (if applicable): N/A

Name: RHEE, HELEN

Covered Official Position (if applicable): N/A

Name: SWIRE, ANDREW

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMGEN INC Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

Corporate Tax Issues

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ANTORCHA, L. NICOLE

Covered Official Position (if applicable): N/A

Name: BEIER, DAVID

Covered Official Position (if applicable): N/A

Name: CURRIE, RODGER

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMGEN INC Client Name: Self

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: JEWEL K. SMITH, PROJECT MANAGER, GLOBAL GOVERNMENT -

Registrant Name: AMGEN INC Client Name: Self

### Information Update Page:

Complete **ONLY** where registration information has changed.

#### LOBBYIST UPDATE

23. Name of each previously reported individual who is **NO LONGER** expected to act as a lobbyist for the client

Name: LINTHICUM, KIMBERLY

#### ISSUE UPDATE

24. General lobbying issues previously reported that **NO LONGER** pertain

TRD

#### AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is **NO LONGER** affiliated with the registrant or client

#### FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the **NO LONGER** owns, **OR** controls, **OR** is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: -